Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTXGet Rating) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

NASDAQ:AKTX opened at $0.99 on Wednesday. Akari Therapeutics has a one year low of $0.95 and a one year high of $1.88. The firm has a market cap of $58.46 million, a P/E ratio of -2.37 and a beta of 1.25. The firm has a 50-day simple moving average of $1.12 and a 200-day simple moving average of $1.27.

Akari Therapeutics (NASDAQ:AKTXGet Rating) last issued its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter.

Several institutional investors have recently modified their holdings of the company. Omnia Family Wealth LLC grew its position in shares of Akari Therapeutics by 13.7% in the 1st quarter. Omnia Family Wealth LLC now owns 758,144 shares of the biopharmaceutical company’s stock worth $910,000 after buying an additional 91,059 shares during the last quarter. Hikari Power Ltd grew its position in shares of Akari Therapeutics by 45.7% in the 1st quarter. Hikari Power Ltd now owns 130,821 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 41,006 shares during the last quarter. Finally, Wsfs Capital Management LLC purchased a new position in shares of Akari Therapeutics in the 4th quarter worth approximately $150,000. 2.50% of the stock is currently owned by hedge funds and other institutional investors.

Akari Therapeutics Company Profile (Get Rating)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.

Featured Articles

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.